Business
GameStop pt. 2: How does GameStop's rising share price affect the actual company?

GameStop pt. 2: How does GameStop's rising share price affect the actual company?

We're all aware by now of how a group of amateur traders have stuck it to a few of the Wall Street elite (catch up here if this is news to you) — but not many stories have focused on how this actually affects GameStop as a company.

We dug out the last 10 years of financial results for GameStop, and they tell the story we now all know — that being a brick-and-mortar video game retailer was a tough gig in an increasingly digital market. Modest profits for much of the last decade gave way to declining revenues and more than $1bn of losses in the last two fiscal years.

Is GameStop set to flourish?

Of course, somewhat ironically, the greatly increased share price of GME doesn't affect the day-to-day operations of the company in the slightest. Shareholders are a lot richer, but the business of selling video games and consoles is unchanged. Under more normal circumstances, a soaring share price could be cashed in — the company could issue new shares to meet the overwhelming demand and then use that cash to invest in the business. That's something Tesla has done 3 times since its stock took off last year.

The problem GameStop has is that this situation is anything but normal. Demand for its shares is likely to eventually disappear just as quickly as it arrived, and the entire point of the short squeeze is that it is predicated on a relatively thin supply of shares being available for sale in the market.

GameStop issuing a few million new shares could kill the momentum but at the current ~$300 price would raise a few billion of fresh capital, helping the company to survive and thrive long after this story ends.

In more "normal" situations an investment bank would often underwrite such an offering, guaranteeing a certain (usually slightly discounted) price for those new shares. The problem is we can't imagine many are willing to do so when GME is regularly up or down 50% over the space of a few hours or even minutes.

More Business

See all Business
The Sphere In Las Vegas

Washington D.C. looks set to get America’s second Sphere

Revenue for the Las Vegas version of the big orb has soared, but the sphere is still a money pit.

business

Ford reportedly in talks to buy hybrid vehicle batteries from Chinese auto giant BYD

Detroit’s Ford and China’s BYD are said to be in ongoing talks to partner on an agreement that would see Ford buy hybrid vehicle batteries from BYD, according to reporting from The Wall Street Journal.

The report comes just days after President Trump toured a Ford factory in Michigan and implied openness to Chinese automakers coming to the US.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

“If they want to come in and build a plant... that’s great, I love that,” Trump said on January 13. “Let China come in, let Japan come in.”

Last week, China’s Geely Automobile Holdings said it expects to make an announcement about expanding into the US within the next three years. Chinese carmakers currently face huge tariffs and software restrictions, effectively barring their vehicles from the US.

Ford has doubled down on hybrid vehicles amid high EV costs and the end of federal EV tax credits. The automaker is currently building a battery plant in Michigan where it plans to use tech from Chinese battery maker CATL.

Still life of Ozempic and Wegovy with weight scale.

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs.

Handshake

Big Pharma enters 2026 with an appetite for deals

At the JPMorgan Healthcare Conference, biotechs and Big Pharma signaled they’re primed for M&A this year, after a big year for deals in 2025.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.